Bio-Techne to Host Conference Call on February 4, 2026, to Announce Second Quarter Fiscal 2026 Financial Results
Rhea-AI Summary
Bio-Techne (NASDAQ: TECH) will host a conference call and webcast on Wednesday, February 4, 2026 at 8:00 a.m. CST to review second quarter fiscal 2026 financial results.
Live access: dial 1-800-579-2543 or 1-785-424-1789 (international) using Conference ID TECHQ2, or join the webcast at https://investors.bio-techne.com/ir-calendar. A recorded rebroadcast will be available from 11:00 a.m. CST on Feb 4, 2026 through 11:00 p.m. CST on Mar 4, 2026 by dialing 1-844-512-2921 or 1-412-317-6671 and referencing Conference ID 11160826.
Positive
- None.
Negative
- None.
News Market Reaction – TECH
In the Jan 20 session, TECH gained 1.30%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 23 | Conference appearance | Positive | +0.5% | Announced CEO presentation at 2026 J.P. Morgan Healthcare Conference. |
| Dec 11 | Strategic partnership | Positive | -0.9% | Partnered with Wyss Center to advance automated 3D multiomics workflows. |
| Dec 09 | Product launch | Positive | -2.4% | Launched enhanced Leo System for high‑throughput, multiplexed protein analysis. |
| Nov 25 | Investor conferences | Positive | +3.7% | Planned presentations at three December 2025 healthcare investor conferences. |
| Nov 18 | Licensing deal | Positive | -0.8% | Licensed AI‑designed NovoBody Duo molecules to expand protein portfolio. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent strategically positive announcements (partnerships, product launches, conferences) often showed mixed or negative next-day price reactions, indicating a tendency toward divergence from seemingly favorable news.
Over the last few months, Bio‑Techne reported several strategic updates. A licensing deal for AI‑designed NovoBody™ Duo molecules on Nov 18, 2025 and a 3D multiomics collaboration with the Wyss Center on Dec 11, 2025 highlighted innovation in proteins and spatial biology. The enhanced Leo™ system launch on Dec 9, 2025 and multiple investor conference appearances, including the upcoming 2026 J.P. Morgan Healthcare Conference, reinforced commercial and investor outreach. The newly announced Q2 FY2026 earnings call date continues this cadence of investor-focused communication following Q1 FY2026 results filed on Nov 5, 2025.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Access to the discussion may be obtained as follows:
Time: | 8:00 a.m. CST |
Date: | February 4, 2026 |
Dial-in: | 1-800-579-2543 or 1-785-424-1789 (for international callers) |
Conference ID: | TECHQ2 |
Webcast: |
A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-844-512-2921 or 1-412-317-6671 (for international callers) and referencing Conference ID 11160826.
The replay will be available from 11:00 a.m. CST on Wednesday, February 4, 2026, until 11:00 p.m. CST on Wednesday, March 4, 2026.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over
Contact: | David Clair, Vice President, Investor Relations |
612-656-4416 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-to-host-conference-call-on-february-4-2026-to-announce-second-quarter-fiscal-2026-financial-results-302663784.html
SOURCE Bio-Techne Corporation